Bristol-Myers Squibb Company
A biopharmaceutical company that discovers and sells medicines for cancer, heart, immune, and brain conditions, with well-known brands like the immunotherapy Opdivo, the blood thinner Eliquis, and the cell therapy Breyanzi. It was formed in 1989 when two old American drugmakers merged: Bristol-Myers, started in 1887 by two college friends who bought a struggling New York firm, and Squibb, founded in 1858 by a doctor who supplied the Union Army during the Civil War. A fun early hit for the Bristol-Myers side was Sal Hepatica, a mineral-salt laxative meant to mimic natural mineral waters.
Bristol-Myers Squibb Contingent Value Right (Celgene acquisition) — Expired Dec 31, 2020
Granted 213.8K · Sold 65.0K
Granted 664.3K · Sold 425.0K
Sold 51.1K
Granted 324.3K · Bought 7.1K · Sold 29.5K
Granted 506.4K · Sold 220.0K
Granted 149.3K · Bought 7.9K
Granted 271.6K · Sold 190.2K
Granted 58.2K
Bought 8.5K
Granted 46.3K
Granted 38.5K · Sold 732
Granted 23.4K
Granted 70.1K · Sold 70.4K
Granted 67.9K
Granted 26.7K · Sold 97.39
Granted 68.3K
Granted 28.6K
Granted 18.9K · Sold 1.2K
Granted 11.1K · Sold 6.6K
Granted 23.9K · Sold 378
Granted 19.1K
Granted 20.0K
Granted 5.4K
Granted 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leung SandraEVP, General Counsel · 54 transactions | — | 455.5Kas of Mar 2025 | 213.8K | — | 65.0K |
| Caforio GiovanniExecutive Chair of the Board, Director · 49 transactions | -24% | 386.8Kas of Mar 2024 | 664.3K | — | 425.0K |
| von Autenried PaulEVP, Chief Information Officer · 3 transactions | — | 292.9Kas of Nov 2021 | — | — | 51.1K |
| Boerner Christopher S.Chief Executive Officer, Director · 83 transactions | — | 261.7K | 324.3K | 7.1K | 29.5K |
| Elkins David VEVP, Chief Financial Officer · 65 transactions | +98.9% | 159.5K | 506.4K | — | 220.0K |
| Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. · 46 transactions | +405% | 83.5Kas of Apr 2025 | 149.3K | 7.9K | — |
| Vessey RupertEVP & President, Research · 43 transactions | +12.3% | 48.4Kas of May 2023 | 271.6K | — | 190.2K |
| Lenkowsky AdamEVP, Chief Commercial Officer · 38 transactions | — | 46.8K | 58.2K | — | — |
| Samuels Theodore R. IIDirector · 1 transaction | — | 38.1Kas of Nov 2023 | — | 8.5K | — |
| Mily ElizabethEVP, Strategy & BD · 22 transactions | +879.6% | 35.9Kas of Apr 2023 | 46.3K | — | — |
| Plenge Robert MEVP, Chief Research Officer · 33 transactions | — | 34.8K | 38.5K | — | 732 |
| Haller Julia ADirector · 2 transactions | +219.4% | 34.1K | 23.4K | — | — |
| Powell AnnEVP, Chief Human Resources · 34 transactions | -41.5% | 27.9Kas of Aug 2023 | 70.1K | — | 70.4K |
| Shanahan KarinEVP, Chief Supply Chain & Ops · 31 transactions | — | 27.3K | 67.9K | — | — |
| Hickey BenjaminPresident, RayzeBio Org. · 9 transactions | — | 25.6K | 26.7K | — | 97.39 |
| Meyers Gregory ScottEVP, Chief Digital & Tech Off. · 31 transactions | — | 24.6K | 68.3K | — | — |
| Gallman CariEVP, General Counsel · 38 transactions | — | 17.0K | 28.6K | — | — |
| Holzer Phil MSVP and Controller · 32 transactions | — | 16.9K | 18.9K | — | 1.2K |
| Santiago Karen MurphySVP & Controller · 16 transactions | +15.2% | 16.7Kas of Mar 2022 | 11.1K | — | 6.6K |
| Short Bartie WendyEVP, Corporate Affairs · 17 transactions | — | 16.0K | 23.9K | — | 378 |
| Poole Ahn AmandaEVP, Chief People Officer · 30 transactions | — | 6.1K | 19.1K | — | — |
| Hoch LynellePresident, Cell Therapy Org. · 30 transactions | — | 5.9K | 20.0K | — | — |
| Weese MichelleEVP, Corporate Affairs · 7 transactions | — | 3.5Kas of Jul 2023 | 5.4K | — | — |
| Greenlees SharonSVP & Controller · 5 transactions | — | 609as of May 2023 | 1.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.04M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.